aid: revagenix
name: Revagenix
description: 'Revagenix, Inc. is a private clinical-stage precision-therapeutics company
  headquartered in San Francisco, California, founded in 2019 by antibacterial-discovery
  veterans from Achaogen. The company takes a first-principles approach to drug design
  for serious chronic disease, engineering each candidate around target biology, route
  of delivery and tolerability. Its lead program, Rev-56, is a first-in-class inhaled
  precision therapy with a novel mechanism of action targeting chronic Pseudomonas
  infection in non-cystic-fibrosis bronchiectasis (NCFB), a progressive respiratory
  disease affecting an estimated 350,000 to 500,000 adults in the United States; Rev-56
  is entering Phase 1 clinical development in 2026, with a dry-powder formulation
  approaching candidate selection. Revagenix is backed by Novo Holdings, Tenmile, the
  REPAIR Impact Fund and the National Institute of Allergy and Infectious Diseases
  (NIAID contract 75N93022C00061). Revagenix is a therapeutics developer, not a software
  vendor: it publishes no API, SDK, developer portal or machine-readable contract.'
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: false
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
image: https://cdn.prod.website-files.com/615238718d430c9069b2aa1f/6167c5a4be0897de151aaa5e_open-graph.png
url: https://raw.githubusercontent.com/api-evangelist/revagenix/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enriched
specificationVersion: '0.20'
created: '2026-08-26'
modified: '2026-08-26'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Therapeutics
- Anti-Infectives
- Respiratory
- Clinical Stage
- Drug Discovery
- Private Company
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/revagenix-domain-security.yml
- type: Website
  url: https://www.revagenix.com/
- type: About
  url: https://www.revagenix.com/company
- type: Pipeline
  url: https://www.revagenix.com/pipeline
- type: Team
  url: https://www.revagenix.com/team
- type: Blog
  url: https://www.revagenix.com/news
- type: Support
  url: https://www.revagenix.com/contact
- type: LinkedIn
  url: https://www.linkedin.com/company/revagenix-inc
- type: Careers
  url: https://www.linkedin.com/company/revagenix-inc/jobs/
- type: LLMsTxt
  url: llms/revagenix-llms.txt
x-enrichment:
  date: '2026-08-26'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: >-
    Revagenix is a 15-person clinical-stage biopharma whose product is Rev-56, an inhaled
    drug entering Phase 1 in 2026; its entire web presence is a six-page Webflow marketing
    site (company, pipeline, team, news, contact) with no developer section, no GitHub
    organization, and no api./docs./developer. subdomain in DNS.
  evidence:
  - url: https://www.revagenix.com/
    status: 200
  - url: https://www.revagenix.com/openapi.json
    status: 404
  - url: https://www.revagenix.com/.well-known/api-catalog
    status: 404
  - url: https://api.github.com/orgs/revagenix
    status: 404
  checked: '2026-08-26'